Abstract 5112
Background
Most cancer patients are treated and followed up on an outpatient basis. A nursing led model of telephone care attention for cancer patients can be useful to improve the symptomatic control and the toxicity of the treatment. This model is being implemented in our hospital belonging to the Andorran Health Care Service. The specific aims of this study is to assess a nursing led model of telephone care attention for cancer patients in the course of treatment.
Methods
A descriptive prospective design has been used to analyze the telephone calls of cancer patients in treatment between outpatient appointments and the resolution capacity of oncology nurses. Telephone calls have been collected from October 2018 to March 2019 in a database. The variables analyzed using this database were: age, sex, type of tumor, type of treatment (oral or intravenous chemotherapy or immunotherapy), call reason and nursing resolution.
Results
49 telephone calls and 52 call reasons have been registered of 45 patients. On average, the patients were 58.1 (± 9.4) years old and 53% of them were male. Patients with colon and breast cancer were the most frequent, representing 20% and 16% respectively. 47% of patients were receiving intravenous chemotherapy, 36% oral chemotherapy and 18% immunotherapy. The call reasons were: 33% related to disease symptoms, 24 % related to toxicity, and 21 % related to treatment information and general issues. The most frequent reason for consultation was pain (23%) and the second was diarrhea (15%). Of the total telephone calls received, 92% were resolved by the nurse compared to 8% who required attention by a physician (p < 0.001).
Conclusions
Oncology nurse led model of telephone support for patients with cancer who attend outpatient treatment can improve symptomatic and toxicity management, reducing medical appointments and admissions to the Emergency Service.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Nostra Senyora de Meritxell.
Funding
Has not received any funding.
Disclosure
G. Simó: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. C. Royo: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Mahia: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Baillés: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Echevarria: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. A. Berenguer: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Albiol: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract